Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase ...

They say that change takes time. Well, that's not the case for RNA. The small biological molecule acts like a switchboard operator, capable of changing its shape every few milliseconds so it can ...

Aardvark claims the two mechanisms could be complementary and even boost the effects of popular “incretin” drugs like Wegovy. That hasn’t been proven in testing, though. Aardvark will evaluate the ...